Though the role of TZDs as an insulin-sensitizing treatment conferring benefit to the cardiovascular system would, in theory, be of advantage in future treatments of cardiovascular events associated with high insulin resistance states, clinical trials have not been able to support it. The gene discussed is INS; the disease is Insulin resistance.